troglitazone has been researched along with Calcification, Pathologic in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, YB | 1 |
| Zhang, J | 1 |
| Peng, DQ | 1 |
| Chang, JR | 1 |
| Cai, Y | 1 |
| Yu, YR | 1 |
| Jia, MZ | 1 |
| Wu, W | 1 |
| Guan, YF | 1 |
| Tang, CS | 1 |
| Qi, YF | 1 |
1 other study available for troglitazone and Calcification, Pathologic
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor γ ligands retard cultured vascular smooth muscle cells calcification induced by high glucose.
Topics: Anilides; Animals; Biomarkers; Calcinosis; Cells, Cultured; Chromans; Dose-Response Relationship, Dr | 2013 |